Bristol Myers Squibb (CELG-RI) EPS (Basic) (2009 - 2026)

Bristol Myers Squibb has disclosed EPS (Basic) across 18 years of filings, most recently posting $1.31 for Q1 2026.

• In Q1 2026, EPS (Basic) rose 8.44% year-over-year to $1.31; the TTM figure through Mar 2026 stood at $3.57 (up 36.11% YoY), while the FY2025 annual figure was $3.47, up 178.72% from the prior year.
• EPS (Basic) grew to $1.31 in Q1 2026, from $0.53 in the prior quarter.
• Over the last five years, EPS (Basic) for CELG-RI reached as high as $7.76 in Q1 2023 and fell as low as -$5.89 in Q1 2024.
• The 5-year median for EPS (Basic) is $1.08 (2025), against an average of $2.28.
• Annual changes were most pronounced in 2024 — EPS (Basic) plunged 175.82% — and 2025, when it jumped 1324.03%.
• A 5-year view of EPS (Basic) shows it stood at $6.93 in 2022, then plunged by 88.1% to $0.83 in 2023, then slumped by 95.46% to $0.04 in 2024, then surged by 1324.03% to $0.53 in 2025, then jumped by 146.2% to $1.31 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered $1.31, $0.53, and $1.08 for Q1 2026, Q4 2025, and Q3 2025 respectively.